Selpercatinib (new indication: non-small cell lung cancer (NSCLC), RET fusion-positive, 1st line)



  • Active Substance: Selpercatinib
  • Name: Retsevmo®
  • Therapeutic area: Non-small cell lung cancer (NSCLC)
  • Pharmaceutical company: Lilly Deutschland GmbH


Time table:

  • Start: 01.07.2022
  • Final decision by G-BA: 15.12.2022
  • The decision remains valid until: 31.12.2025


Final decision:

  1. Patients with PD-L1 expression in ≥ 50% of tumor cells: No additional benefit proved
  2. Patients with PD-L1 expression in < 50 % of tumor cells: No additional benefit proved